glp 1 in type 1 diabetes for weight loss The Benefits of GLP-1 Therapy: Beyond GLP-1 and GIP–GLP-1 therapies benefits

PMC 3096450

Clinically Studied L-Glutathione

The evaluation of side effects is based on the following frequency information: Very common: more than 1 in 10 people treated Common: less than 1 in 10 but more than 1 in 100 people treated Uncommon: less than 1 in 100 but more than 1 in 1000 people treated Rare: less than 1 in 1,000 but more than 1 in 10,000 people treated Very rare: less than 1 in 10,000 people treated, or unknown

The drug has been approved for prescription to UK adults with a body mass index of 30 or above, or who are overweight with a BMI between 27 and 30 and at least one weight-related condition